WallStSmart
ZLAB

Zai Lab Ltd

NASDAQ: ZLAB · HEALTHCARE · BIOTECHNOLOGY

$19.59
-4.15% today

Updated 2026-06-05

Market cap
$2.07B
P/E ratio
P/S ratio
4.58x
EPS (TTM)
$-1.70
Dividend yield
52W range
$16 – $44
Volume
0.8M

Zai Lab Ltd (ZLAB) Financial statements

SEC filings — annual and quarterly data.

Profit margin
-38.15%
Operating margin
-48.59%
ROE
-26.91%
ROA
-13.40%
Debt/equity
0.35x

Margin trends — annual

Gross margin Operating margin Profit margin
YearRevenueNet incomeGross marginOp. marginProfit margin
2015$0.00$-18.02M
2016$0.00$-37.51M
2017$0.00$-50.38M
2018$129452.00$-139.07M66.33%-109,514.01%-107,433.56%
2019$12.98M$-183.37M71.13%-1,564.88%-1,412.16%
2020$48.96M$-268.90M-389.09%-616.45%-549.26%
2021$144.31M$-704.47M63.80%-485.10%-488.16%
2022$215.04M$-443.29M65.58%-188.04%-206.14%
2023$266.72M$-334.62M64.08%-137.44%-125.46%
2024$398.99M$-257.10M62.94%-70.71%-64.44%
2025$460.16M$-175.54M58.47%-48.59%-38.15%

Frequently asked questions

What is Zai Lab Ltd's revenue?

Zai Lab Ltd's trailing twelve-month revenue is $453.28M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.

How profitable is ZLAB?

In its most recent fiscal year, ZLAB ran a gross margin of 58.47%, an operating margin of -48.59%, and a net margin of -38.15%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.

How much free cash flow does ZLAB generate?

ZLAB produced $-158.89M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is ZLAB's balance sheet healthy?

ZLAB holds $679.57M in cash and equivalents against — in long-term debt, on $715.50M of shareholder equity. That debt is best read against the cash flow the business throws off each year.